Analgesic use may decrease postmenopausal estrogen levels

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 4
Volume 19
Issue 4

Postmenopausal women who regularly use painkillers have lower estrogen levels, which could lead to a decreased risk of breast or ovarian cancer.

Postmenopausal women who regularly use painkillers have lower estrogen levels, which could lead to a decreased risk of breast or ovarian cancer, according to researchers at Boston's Brigham and Women's Hospital and Harvard Medical School (Cancer Epidemiol Biomarkers Prev online, March 23, 2010).

The investigators looked at the link between the use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), and acetaminophen and concentrations of estrogens and androgens among 740 postmenopausal women who participated in the Nurses' Health Study. The frequency of all analgesic use was inversely associated with estradiol, free estradiol, estrone sulfate, and the ratio of estradiol to testosterone. The average estradiol levels were 10.5% lower among women who regularly used aspirin or non-aspirin NSAIDs. Free estradiol levels were 10.6% lower and estrone sulfate levels were 11.1% lower among regular users of aspirin.

Recent Videos
A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
Investigators evaluated ctDNA as a potentially noninvasive method to predict response to radiotherapy among those with gynecologic malignancies.
The Foundation for Women’s Cancer provides multicultural resources for patients with gynecologic cancers to help address gaps in care.
Ginger J. Gardner, MD, FACOG, addresses the growing uterine cancer cases among patients in the United States and the need for greater genetic testing.
Ginger J. Gardner, MD, FACOG, discussed the state of gynecologic cancers and her role in empowering research, education, and awareness surrounding them.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Related Content